Cargando…
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
Through the use of surrogate markers of efficacy, neoadjuvant studies may facilitate the implementation of new treatments into clinical practice. However, disease-free survival is the current standard outcome endpoint for registration of a novel treatment. The coupling of smaller neoadjuvant 'p...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687702/ https://www.ncbi.nlm.nih.gov/pubmed/19216727 http://dx.doi.org/10.1186/bcr2209 |